Overview

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
0
Participant gender:
Male
Summary
This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Minoxidil
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss
for at least 1 year

- Willingness to have micro-dot-tattoo applied to scalp

- Willingness to maintain same hair style, length and hair color during study

Exclusion Criteria:

- Drug or alcohol abuse within 12 months

- HIV positive

- Received hair transplants or had scalp reductions

- Use of hair weaves, hair extensions or wigs within 3 months

- Oral or topical minoxidil treatment within 6 months

- Application of topical steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) to
scalp within 4 weeks